NCT00901069 - Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

November 30, 2012

Conditions

LymphomaHodgkin DiseaseLymphoma, Non-Hodgkin

Interventions

DRUG

Azacitidine with rituximab, vincristine, and cyclophosphamide

Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^

Trial Locations (1)

40536

University of Kentucky, Lexington